p53 protein transduction therapy

Successful targeting and inhibition of the growth of the bladder cancer cells

Miyabi Inoue, Kazuhito Tomizawa, Masayuki Matsushita, Yun Fei Lu, Teruhiko Yokoyama, Hiroyuki Yanai, Atsushi Takashima, Hiromi Kumon, Hideki Matsui

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Introduction: Virus-mediated gene therapy for bladder cancer has some problems, such as efficiency of gene delivery and safety issues. We have reported that poly-arginine peptide (11R) has the ability to increase protein transduction in cells. Here, we show that p53 protein transduction using 11R is useful for targeting to bladder tumors and suppressing the growth of bladder cancer cells. Materials and methods: An 11R-fused p53 protein (11R-p53) was transduced in bladder cancer cell lines (J82 and T24) to evaluate the anti-tumor effect. Cell viability was assessed by performing the 4-[3-(4-iodophenyl)-2-(4- nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST) assay. To investigate whether 11R-p53 enhanced the effect on anti-cancer drug-dependent apoptosis of bladder cancer cells, the cell lines were cotreated with 11R-p53 and cis-diaminedichloroplatinum (CDDP). Apoptotic cells were identified using Hoechst staining. To investigate the efficiency of protein transduction mediated by 11R in bladder tumors in vivo, SCID mice were transplanted with J82 cells in the bladder and 11R-GFP was transurethrally transduced into the bladder. The transduction of 11R-GFP in the tumor was examined by confocal microscopy. Results: 11R-p53 inhibited the growth of both J82 and T24 cells in a dose-dependent manner. The transduction of 11R-p53 enhanced CDDP-dependent induction of apoptosis. Transurethral application of 11R-GFP resulted in transduction of GFP in bladder tumors but not in the normal bladder epithelium or subepithelial tissues. Conclusion: The present results suggest that p53 protein transduction therapy may be a promising method for the treatment of bladder cancer.

Original languageEnglish
Pages (from-to)161-168
Number of pages8
JournalEuropean Urology
Volume49
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Urinary Bladder Neoplasms
Growth
Proteins
Urinary Bladder
Therapeutics
Apoptosis
Cell Line
Neoplasms
SCID Mice
Confocal Microscopy
Genetic Therapy
Arginine
Cell Survival
Epithelium
Staining and Labeling
Viruses
Safety
Peptides
Pharmaceutical Preparations
Genes

Keywords

  • Adenovirus
  • Bladder epithelium
  • Gene therapy
  • Protein deliverly
  • TAT

ASJC Scopus subject areas

  • Urology

Cite this

p53 protein transduction therapy : Successful targeting and inhibition of the growth of the bladder cancer cells. / Inoue, Miyabi; Tomizawa, Kazuhito; Matsushita, Masayuki; Lu, Yun Fei; Yokoyama, Teruhiko; Yanai, Hiroyuki; Takashima, Atsushi; Kumon, Hiromi; Matsui, Hideki.

In: European Urology, Vol. 49, No. 1, 01.2006, p. 161-168.

Research output: Contribution to journalArticle

Inoue, Miyabi ; Tomizawa, Kazuhito ; Matsushita, Masayuki ; Lu, Yun Fei ; Yokoyama, Teruhiko ; Yanai, Hiroyuki ; Takashima, Atsushi ; Kumon, Hiromi ; Matsui, Hideki. / p53 protein transduction therapy : Successful targeting and inhibition of the growth of the bladder cancer cells. In: European Urology. 2006 ; Vol. 49, No. 1. pp. 161-168.
@article{0408bc23b10c4400ac1267c4c5a7fe45,
title = "p53 protein transduction therapy: Successful targeting and inhibition of the growth of the bladder cancer cells",
abstract = "Introduction: Virus-mediated gene therapy for bladder cancer has some problems, such as efficiency of gene delivery and safety issues. We have reported that poly-arginine peptide (11R) has the ability to increase protein transduction in cells. Here, we show that p53 protein transduction using 11R is useful for targeting to bladder tumors and suppressing the growth of bladder cancer cells. Materials and methods: An 11R-fused p53 protein (11R-p53) was transduced in bladder cancer cell lines (J82 and T24) to evaluate the anti-tumor effect. Cell viability was assessed by performing the 4-[3-(4-iodophenyl)-2-(4- nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST) assay. To investigate whether 11R-p53 enhanced the effect on anti-cancer drug-dependent apoptosis of bladder cancer cells, the cell lines were cotreated with 11R-p53 and cis-diaminedichloroplatinum (CDDP). Apoptotic cells were identified using Hoechst staining. To investigate the efficiency of protein transduction mediated by 11R in bladder tumors in vivo, SCID mice were transplanted with J82 cells in the bladder and 11R-GFP was transurethrally transduced into the bladder. The transduction of 11R-GFP in the tumor was examined by confocal microscopy. Results: 11R-p53 inhibited the growth of both J82 and T24 cells in a dose-dependent manner. The transduction of 11R-p53 enhanced CDDP-dependent induction of apoptosis. Transurethral application of 11R-GFP resulted in transduction of GFP in bladder tumors but not in the normal bladder epithelium or subepithelial tissues. Conclusion: The present results suggest that p53 protein transduction therapy may be a promising method for the treatment of bladder cancer.",
keywords = "Adenovirus, Bladder epithelium, Gene therapy, Protein deliverly, TAT",
author = "Miyabi Inoue and Kazuhito Tomizawa and Masayuki Matsushita and Lu, {Yun Fei} and Teruhiko Yokoyama and Hiroyuki Yanai and Atsushi Takashima and Hiromi Kumon and Hideki Matsui",
year = "2006",
month = "1",
doi = "10.1016/j.eururo.2005.08.019",
language = "English",
volume = "49",
pages = "161--168",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - p53 protein transduction therapy

T2 - Successful targeting and inhibition of the growth of the bladder cancer cells

AU - Inoue, Miyabi

AU - Tomizawa, Kazuhito

AU - Matsushita, Masayuki

AU - Lu, Yun Fei

AU - Yokoyama, Teruhiko

AU - Yanai, Hiroyuki

AU - Takashima, Atsushi

AU - Kumon, Hiromi

AU - Matsui, Hideki

PY - 2006/1

Y1 - 2006/1

N2 - Introduction: Virus-mediated gene therapy for bladder cancer has some problems, such as efficiency of gene delivery and safety issues. We have reported that poly-arginine peptide (11R) has the ability to increase protein transduction in cells. Here, we show that p53 protein transduction using 11R is useful for targeting to bladder tumors and suppressing the growth of bladder cancer cells. Materials and methods: An 11R-fused p53 protein (11R-p53) was transduced in bladder cancer cell lines (J82 and T24) to evaluate the anti-tumor effect. Cell viability was assessed by performing the 4-[3-(4-iodophenyl)-2-(4- nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST) assay. To investigate whether 11R-p53 enhanced the effect on anti-cancer drug-dependent apoptosis of bladder cancer cells, the cell lines were cotreated with 11R-p53 and cis-diaminedichloroplatinum (CDDP). Apoptotic cells were identified using Hoechst staining. To investigate the efficiency of protein transduction mediated by 11R in bladder tumors in vivo, SCID mice were transplanted with J82 cells in the bladder and 11R-GFP was transurethrally transduced into the bladder. The transduction of 11R-GFP in the tumor was examined by confocal microscopy. Results: 11R-p53 inhibited the growth of both J82 and T24 cells in a dose-dependent manner. The transduction of 11R-p53 enhanced CDDP-dependent induction of apoptosis. Transurethral application of 11R-GFP resulted in transduction of GFP in bladder tumors but not in the normal bladder epithelium or subepithelial tissues. Conclusion: The present results suggest that p53 protein transduction therapy may be a promising method for the treatment of bladder cancer.

AB - Introduction: Virus-mediated gene therapy for bladder cancer has some problems, such as efficiency of gene delivery and safety issues. We have reported that poly-arginine peptide (11R) has the ability to increase protein transduction in cells. Here, we show that p53 protein transduction using 11R is useful for targeting to bladder tumors and suppressing the growth of bladder cancer cells. Materials and methods: An 11R-fused p53 protein (11R-p53) was transduced in bladder cancer cell lines (J82 and T24) to evaluate the anti-tumor effect. Cell viability was assessed by performing the 4-[3-(4-iodophenyl)-2-(4- nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST) assay. To investigate whether 11R-p53 enhanced the effect on anti-cancer drug-dependent apoptosis of bladder cancer cells, the cell lines were cotreated with 11R-p53 and cis-diaminedichloroplatinum (CDDP). Apoptotic cells were identified using Hoechst staining. To investigate the efficiency of protein transduction mediated by 11R in bladder tumors in vivo, SCID mice were transplanted with J82 cells in the bladder and 11R-GFP was transurethrally transduced into the bladder. The transduction of 11R-GFP in the tumor was examined by confocal microscopy. Results: 11R-p53 inhibited the growth of both J82 and T24 cells in a dose-dependent manner. The transduction of 11R-p53 enhanced CDDP-dependent induction of apoptosis. Transurethral application of 11R-GFP resulted in transduction of GFP in bladder tumors but not in the normal bladder epithelium or subepithelial tissues. Conclusion: The present results suggest that p53 protein transduction therapy may be a promising method for the treatment of bladder cancer.

KW - Adenovirus

KW - Bladder epithelium

KW - Gene therapy

KW - Protein deliverly

KW - TAT

UR - http://www.scopus.com/inward/record.url?scp=29044436777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29044436777&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2005.08.019

DO - 10.1016/j.eururo.2005.08.019

M3 - Article

VL - 49

SP - 161

EP - 168

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -